Lobe Sciences Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lobe Sciences Ltd. (CSE: LOBE; OTCQB: LOBEF) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs, including chronic cluster headache (CCH) and sickle cell disease (SCD). The company researches and develops proprietary psychedelic-derived compounds using sub-hallucinatory doses to improve brain health, mental wellness, and neurological conditions; its lead candidate, Conjugated Psilocin (CP), a newly patented chemical entity (NCE), targets CCH through its subsidiary Cynaptec Pharmaceuticals Inc., which holds related worldwide intellectual property; additional pipeline assets include L-130 and L-131, synthetic psilocin analogues for CCH, pediatric anxiety, and other orphan neurological disorders; and Altemia, a proprietary medical food formulated as an oral emulsion to address long-chain fatty acid metabolism errors in adult and pediatric SCD patients, as well as applications in diabetes and chronic kidney disease. Lobe Sciences operates primarily in Canada with global development ambitions, including clinical trials in Australia via its wholly-owned subsidiary Lobe Sciences Australia Pty Ltd. Founded in 2018 and headquartered in Vancouver, British Columbia, the company was formerly known as Greenstar Biosciences Corp. until its name change in November 2020. In recent developments, Lobe Sciences completed a US$500,000 convertible note financing in June 2024 with strategic partners Clearway Global LLC and Quality Chemical Laboratories Inc. to address accounts payable, support legal costs, and bridge to a larger funding round anticipated in late 2024 or early 2025, while converting short-term debt to long-term instruments to strengthen its balance sheet. The company launched Cynaptec Pharmaceuticals Inc. in April 2025 as a 64%-owned standalone entity with a separate board and executive team to advance Conjugated Psilocin through pre-clinical, Phase 1, and Phase 2a studies, backed by a US$6 million private placement and an optional US$20 million for Phase 3; it also secured a notice of allowance for a second U.S. patent on Conjugated Psilocin with partner Alera Pharma in November 2024. Further strategic moves include appointing Yong Yao as Chief Financial Officer in June 2025 to drive growth, naming Dr. Herman Williams as CEO of Altemia Inc. in March 2025, engaging Enclave Capital and Peak Asset Management in October 2025 to fund Conjugated Psilocin clinical trials, pursuing up-listing to the New York Stock Exchange and Australian Securities Exchange, and evaluating out-licensing opportunities for assets like L-130 and Altemia.
Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026
Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares
Lobe Sciences Announces Proposed Shares for Debt Transaction
Lobe Sciences Ltd. Announces Participation in the D.
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Lobe Sciences Reports First Quarter 2026 Results and Highlights
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
Lobe Sciences Improves Balance Sheet
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025